Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00025675 · ClinicalTrials.gov registry record · Phase 2
Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors
A Phase 2 study of Brain and Central Nervous System Tumors, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 2
- Development phase
- 105
- Enrollment target
- 12
- Study locations
NCT00025675: Completed Phase 2 study of Brain and Central Nervous System Tumors, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
NCT00025675 is a Phase 2 study of Brain and Central Nervous System Tumors that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 105 participants, below the 181-participant average among 45 other Brain and Central Nervous System Tumors trials with a reported enrollment target (42% lower). The trial reports 12 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00025675, a Phase 2 study of Brain and Central Nervous System Tumors, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 105 participants
- Enrollment target
- 12
- Study locations
Study Summary
RATIONALE: Biological therapies such as gefitinib may interfere with the growth of tumor cells and slow the growth of CNS tumors. PURPOSE: Phase II trial to study the effectiveness of gefitinib in treating patients who have recurrent or progressive CNS tumors.
Conditions Studied
Interventions
- DRUG gefitinib
Study Locations (12)
Texas
- Simmons Cancer Center at University of Texas Southwestern Medical Center - Dallas - Dallas
- M.D. Anderson Cancer Center at University of Texas - Houston
- University of Texas Health Science Center at San Antonio - San Antonio
California
- Jonsson Comprehensive Cancer Center at UCLA - Los Angeles
- UCSF Comprehensive Cancer Center - San Francisco
Maryland
- Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support - Bethesda
- NCI - Neuro-Oncology Branch - Bethesda
Massachusetts
- Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute - Boston
Michigan
- University of Michigan Comprehensive Cancer Center - Ann Arbor
New York
- Memorial Sloan-Kettering Cancer Center - New York
Pennsylvania
- Hillman Cancer Center at University of Pittsburgh Cancer Institute - Pittsburgh
Wisconsin
- University of Wisconsin Comprehensive Cancer Center - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2001-10-09 |
| Est. Completion | 2010-01-02 |
| Phase | Phase 2 |
What the finished NCT00025675 record still lists
NCT00025675 is an interventional study that assigns participants to a tested intervention. The registered 105 participants enrollment target is mid-sized for trials with a published cap, below the 181-participant average among 45 other Brain and Central Nervous System Tumors trials with a reported enrollment target (42% lower).
The record links to 1 condition, with Brain and Central Nervous System Tumors appearing as the primary indexed condition, and to 1 intervention - of which gefitinib is the first listed.
NCT00025675 lists 12 locations in 8 states (Texas, California, Maryland).
Frequently Asked Questions
What is clinical trial NCT00025675 about?
NCT00025675 is a clinical study titled "Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors". RATIONALE: Biological therapies such as gefitinib may interfere with the growth of tumor cells and slow the growth of CNS tumors. PURPOSE: Phase II trial to study the effectiveness of gefitinib in treating patients who have recurrent or progressive CNS tumors.
What is the current status of trial NCT00025675?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 105 participants. The study started on 2001-10-09. Estimated completion is 2010-01-02.
What conditions does trial NCT00025675 study?
This clinical trial studies the following conditions: Brain and Central Nervous System Tumors.
What interventions are being tested in trial NCT00025675?
The interventions under investigation include: gefitinib (DRUG).
Who is sponsoring clinical trial NCT00025675?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00025675 being conducted?
This trial has 12 study locations across California, Maryland, Massachusetts, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain and Central Nervous System Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00025675's enrollment target sits among peer trials
105 13th of 45 higher than 33 of 45 other Brain and Central Nervous System Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Brain and Central Nervous System Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma
ACTIVE NOT RECRUITING · Phase 2
-
Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Evaluating Patients Who Are Undergoing Treatment for Gliomas
COMPLETED · Phase 2
-
Combination Chemotherapy for Patients With Brain Cancer
COMPLETED · Phase 2
-
Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors
COMPLETED · Phase 2
-
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Anaplastic Astrocytoma
COMPLETED · Phase 2
-
Phenylacetate in Treating Children With Recurrent or Progressive Brain Tumors
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03372317 · 105 participants
Tau PET in Imaging and Cognition: Healthy Adults From 55-90
- NCT04253964 · 105 participants · Phase 2
Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy
- NCT04742452 · 105 participants · NA
Comparison of Partial Rotator Cuff Repair vs. Superior Capsular Reconstruction for Irreparable Rotator Cuff Tears
- NCT04875429 · 105 participants · NA
Zenith® Fenestrated+ Clinical Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI